MGCD265 is an orally bioavailable, multitargeted tyrosine kinase inhibitor. It binds to and inhibits the phosphorylation of several receptor tyrosine kinases (RTKs), including the c-Met receptor (hepatocyte growth factor receptor); the Tek/Tie-2 receptor; vascular endothelial growth factor receptor (VEGFR) types 1, 2, and 3; and the macrophage-stimulating 1 receptor (MST1R or RON). It is currently being evaluated clinically in patients with solid tumors that have genetic alterations in MET or AXL genes, which have been implicated as drivers of tumor growth and disease progression in NSCLC, gastroesophageal cancer and other solid tumors.

KEYWORDS: MGCD265 dihydrochloride | Supplier | MET/SMO dual inhibitor. | Glesatinib dihydrochloride | MG265 dihydrochloride | MGCD-265 | MGCD 265 | MG-265 | MG 265 | CT-MG265 | CAS [N.A.] | [936694-12-1] | HGF | c-MET | SMO | Inhibitor | Receptors